AI-enabled medical devices with limited pre-market validation are more likely to be recalled after FDA clearance.
Key Details
- 1AI-enabled device recalls are more common among those lacking prospective human validation prior to FDA 510(k) clearance.
- 2Most AI medical devices are cleared without requiring prospective clinical testing.
- 3Study reviewed all U.S. recalls of AI-enabled devices between Nov. 15–30, 2024.
- 4Validation method (none, retrospective, or prospective) was a notable factor influencing recall likelihood.
- 5Recalls were categorized into errors such as diagnostic, measurement, and functional issues.
Why It Matters
These findings highlight the inadequacy of current FDA pathways to ensure AI device reliability and safety in clinical environments. For radiology professionals and developers, the results underscore the critical importance of robust validation before market approval.
Source
Health Imaging
Related News
•AuntMinnie
AI Tool Mirai Shows Robust Performance for Interval Breast Cancer Detection
The Mirai AI model significantly improves detection of interval breast cancers in negative screening mammograms.
•Radiology Business
AI Tool Predicts Interval Breast Cancer Risk from Negative Mammograms
AI can predict interval breast cancer risk up to three years after a negative mammogram.
•Radiology Business
AI Outperforms Radiologists in Predicting Lung Cancer Treatment Response
AI tools demonstrate higher accuracy than radiologists in predicting lung cancer treatment response from imaging studies.